Markets:

Overview

News

Currencies

International

Treasuries

Immunome, Inc. - Common Stock (NQ:IMNM)

20.39 -1.09 (-5.07%)

Streaming Delayed Price Updated: 11:49 AM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Immunome, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 05, 2025

From Immunome, Inc.

Via Business Wire

Immunome to Present at Upcoming Investor Conferences

May 22, 2025

From Immunome, Inc.

Via Business Wire

Immunome Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025

From Immunome, Inc.

Via Business Wire

Analyst Expectations For Immunome's Future ↗

November 08, 2024

Via Benzinga

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 02, 2025

From Immunome, Inc.

Via Business Wire

Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference

April 04, 2025

From Immunome, Inc.

Via Business Wire

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 03, 2025

From Immunome, Inc.

Via Business Wire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

March 26, 2025

Via Benzinga

Immunome Reports Full Year 2024 Financial Results and Provides Business Update

March 19, 2025

From Immunome, Inc.

Via Business Wire

Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC

March 10, 2025

From Immunome, Inc.

Via Business Wire

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 06, 2025

From Immunome, Inc.

Via Business Wire

Immunome to Present at Upcoming March Conferences

February 25, 2025

From Immunome, Inc.

Via Business Wire

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2025

From Immunome, Inc.

Via Business Wire

Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

January 31, 2025

From Immunome, Inc.

Via Business Wire

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

January 30, 2025

Via Benzinga

Immunome Announces Pricing of Upsized Public Offering of Common Stock

January 29, 2025

From Immunome, Inc.

Via Business Wire

Curious about the stocks that are showing activity after the closing bell on Wednesday? ↗

January 29, 2025

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.

Via Chartmill

Immunome Announces Proposed Public Offering of Common Stock

January 29, 2025

From Immunome, Inc.

Via Business Wire

Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

January 13, 2025

From Immunome, Inc.

Via Business Wire

Hummingbird Bioscience Licenses Novel Antibodies to Immunome

January 07, 2025

From Hummingbird Bioscience

Via GlobeNewswire

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 02, 2025

From Immunome, Inc.

Via Business Wire

3 Small-Cap Stocks With Big Growth Potential

December 13, 2024

Small-cap companies may give investors more targeted exposure to the U.S. economy; these companies are three leaders in the space.

Via MarketBeat

Topics Economy

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 02, 2024

From Immunome, Inc.

Via Business Wire

Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference

November 27, 2024

From Immunome, Inc.

Via Business Wire

Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update

November 13, 2024

From Immunome, Inc.

Via Business Wire

This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗

November 08, 2024

Via Benzinga

Immunome to Present at Guggenheim’s Inaugural Healthcare Innovation Conference

November 05, 2024

From Immunome, Inc.

Via Business Wire

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 01, 2024

From Immunome, Inc.

Via Business Wire

Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021

October 29, 2024

From Immunome, Inc.

Via Business Wire

Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium

October 18, 2024

From Immunome, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.